Expression and clinical significance of fibronectin 1 in breast cancer and its correlation with human epidermal growth factor receptor 2

doi:10.3877/cma.j.issn.1674-0793.2023.03.009

Abstract

Abstract:

Objective

To investigate the correlation between fibronectin 1 (FN1) and human epidermal growth factor receptor 2 (HER2) expression in breast cancer and its significance.

Methods

FN1 expression and invasion ability in HER2-overexpression cells and HER2-negative cells were investigated by RT-PCR and Transwell analysis, respectively. Bioinformatics analysis was carried out for the expression and the correlation between FN1 and HER2 in patients with breast cancer, while R language analysis of the effects of FN1 on the overall survival and the relapse free survival of patients with breast cancer.

Results

The expression of FN1 was significantly increased in HER2-overexpression cells (t=8.660, P=0.000 5), and the migration and invasion ability were stronger than those in HER2-negative cells (t=25.84, 28.38, both P<0.001). Bioinformatics analysis showed that the expression of FN1 in breast cancer tissues was significantly higher than that in normal tissues (P<0.001). In breast cancer tissues, the expression of FN1 was significantly higher in HER2-positive breast cancer than that in HER2-negative breast cancer (t=6.166, P<0.001), and was positively correlated with HER2 expression (P=0.000 2). In HER2-negative breast cancer, high expression of FN1 was associated with a shortened overall survival and the relapse free survival. In HER2-positive breast cancer, FN1 could be used as a predictor of the efficacy of neoadjuvant therapy with herceptin.

Conclusions

There is positive correlation between FN1 and the expression of HER2 in breast cancer. In patients with HER2-negative breast cancer, the expression of FN1 is of great significance in predicting the survival prognosis. In neoadjuvant therapy with herceptin for HER2-positive breast cancer, FN1 has predictive value for the efficacy of herceptin.

Key words: Breast neoplasms, Fibronectin 1, Human epidermal growth factor receptor 2, Herceptin/trastuzumab

Kaiting Yu, Dong Wang, Hao Zhong, Meifang He, Jufang Wang. Expression and clinical significance of fibronectin 1 in breast cancer and its correlation with human epidermal growth factor receptor 2[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 203-210.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.03.009

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I03/203

Figures/Tables 5

References 23

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Ban M, Petrié Miše B, Vrdoljak E. Early HER2-positive breast cancer: current treatment and novel approaches[J]. Breast Care (Basel), 2020, 15(6): 560-569.
[3]	Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer[J]. Chin Clin Oncol, 2020, 9(3): 32.
[4]	Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J]. Lancet, 2017, 389(10075): 1195-1205.
[5]	Hatschek T, Foukakis T, Bjöhle J, et al. Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: A phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(9): 1360-1367.
[6]	Cai X, Liu C, Zhang TN, et al. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion[J]. J Cell Biochem, 2018, 119(6): 4717-4728.
[7]	Liu X, Meng L, Li X, et al. Regulation of FN1 degradation by the p62/SQSTM1-dependent autophagy-lysosome pathway in HNSCC[J]. Int J Oral Sci, 2020, 12(1): 34.
[8]	Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer[J]. Breast, 2015, 24 Suppl 2: S26-S35.
[9]	Li B, Yau T, Leung R, et al. Neoadjuvant therapy with concurrent docetaxel, epirubicin, and cyclophosphamide (TEC) in high-risk HER2-negative breast cancers[J]. Adv Ther, 2021, 38(12): 5752-5762.
[10]	Shafei A, El-Bakly W, Sobhy A, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer[J]. Biomed Pharmacother, 2017, 95: 1209-1218.
[11]	Samaan TMA, Samec M, Liskova A, et al. Paclitaxel's mechanistic and clinical effects on breast cancer[J]. Biomolecules, 2019, 9(12): 789.
[12]	Norum J. Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?[J]. Acta Oncol, 2000, 39(1): 33-39.
[13]	Rugo HS, Im SA, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(4): 573-584.
[14]	Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer[J]. Cancer Cell, 2020, 37(4): 496-513.
[15]	Derakhshani A, Rezaei Z, Safarpour H, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy[J]. J Cell Physiol, 2020, 235(4): 3142-3156.
[16]	Zhang H, Sun Z, Li Y, et al. MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells[J]. Biomed Pharmacother, 2017, 88: 285-292.
[17]	Zhang H, Chen X, Xue P, et al. FN1 promotes chondrocyte differentiation and collagen production via TGF-β/PI3K/Akt pathway in mice with femoral fracture[J]. Gene, 2021, 769: 145253.
[18]	Gao R, Feng Q, Tan G. microRNA-613 exerts anti-angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down-regulating FN1[J]. Biosci Rep, 2019, 39(7): BSR20182196.
[19]	Wang H, Guo S, Kim SJ, et al. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel[J]. Theranostics, 2021, 11(5): 2442-2459.
[20]	Karthikeyan S, Waters IG, Dennison L, et al. Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones[J]. J Clin Invest, 2021, 131(6): e143557.
[21]	Saatci O, Kaymak A, Raza U, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer[J]. Nat Commun, 2020, 11(1): 2416.
[22]	Lambertini M, Pondé NF, Solinas C, et al. Adjuvant trastuzumab: A 10-year overview of its benefit[J]. Expert Rev Anticancer Ther, 2017, 17(1): 61-74.
[23]	Mackay A, Jones C, Dexter T, et al. cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells[J]. Oncogene, 2003, 22(17): 2680-2688.

Please choose a citation manager

Content to export